Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted Novozymes Biopharma DK A/S
Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Related

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

 Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026